Neoadjuvant therapy for pancreatic cancer: an ongoing debate

Affiliations

¹ Case Western Reserve University School of Medicine, Cleveland, OH, USA.
² Tufts University School of Medicine, 800 Washington Street, Suite 7099, 7-S, Boston, MA 02111, USA.

Suzanne Russo et al. Therap Adv Gastroenterol. 2016 Jul.

. 2016 Jul;9(4):429-36.

doi: 10.1177/1756283X16646524. Epub 2016 May 10.

¹ Case Western Reserve University School of Medicine, Cleveland, OH, USA.
² Tufts University School of Medicine, 800 Washington Street, Suite 7099, 7-S, Boston, MA 02111, USA.

No abstract available

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

1. Andriulli A., Festa V., Botteri E., Valvano M., Koch M., Bassi C., et al. (2012) Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19: 1644–1662. - PubMed
1. Beatty G., Chiorean E., Fishman M., Saboury B., Teitelbaum U., Sun W., et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612–1616. - PMC - PubMed
1. Beatty G., Torigian D., Chiorean E., Saboury B., Brothers A., Alavi A., et al. (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19: 6286–6295. - PMC - PubMed
1. Chandler N., Canete J., Stuart K., Callery M. (2003) Preoperative chemoradiation in resectable pancreatic cancer. J Hepatobiliary Pancreat Surg 10: 61–66. - PubMed
1. Dholakia A., Hacker-Prietz A., Wild A., Raman S., Wood L., Huang P., et al. (2013) Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. J Radiat Oncol 2: 413–425. - PMC - PubMed